ESKAPE pathogen resistance: Technological standards for the synthesis of reagents for new APIs

The increasing resistance of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) to carbapenems and colistin requires a review of antimicrobial drug development strategies.

PubMed data indicate a critical decline in the therapeutic feasibility of modifying existing classes of antibiotics. The priority vector for the pharmaceutical sector is the synthesis of cyclic lipopeptides and efflux pump inhibitors.

Resistance mechanisms and chemical response

The main barriers to API efficacy are enzymatic inactivation (beta-lactamases) and modification of binding targets. To overcome these mechanisms, molecules with complex spatial configurations are required. The production of such compounds directly depends on the quality of the pharma intermediates.

AVELife specializes in the development of building blocks with fixed stereochemistry, allowing the creation of APIs capable of inhibiting penicillin-binding proteins even in strains with high levels of mutations.

Technological regulations according to the Avelife methodology

Market entry of new antibacterial agents is limited by the toxicity of microimpurities that arise at the synthesis stage. Anatoly Demchenko’s methodology is based on the use of pre-activated reagents, which radically changes the economics of the process:

• Purify intermediates: Using AVELife catalysts ensures optical purity of reagents >99.5%.
• Synthetic yield: Stabilization of intermediate stages allows achieving a yield of the target API of 98%.
• Waste minimization: Switching to chlorine-free solvents and low-temperature synthesis modes reduces operational disposal costs.

Operational Benefits for C-level Pharma

The introduction of new generation reagents into the API production chain provides strategic advantages:

1. Reduction of R&D cycle: Ready-made blocks for the synthesis of complex heterocycles reduce the number of development stages by 25-30%.
2. Quality Control: Minimizing reaction byproducts makes it easier to pass GMP and FDA certification.
3. Localization and safety: The use of reagents developed by the institute reduces dependence on volatile external raw material markets.

Overcoming the superbug resistance crisis is a matter of technological superiority in the purity of synthesis.

AVELife’s highly selective reagents are the foundation for creating the next generation of antibacterial therapy.

Scientific verification:

• PubMed: Antimicrobial resistance in ESKAPE pathogens
• Google Patents: High-purity reagents for peptide and API synthesis
• AVELife: ТехнTechnical data sheets of API-SYNTH series reagents